Full-Time

Quality Assurance Lead

Salesforce & Copado Robotic Testing

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
QA & Testing (2)
,
Required Skills
Agile
Software Testing
ServiceNow
Quality Assurance (QA)
Salesforce
JIRA
SCRUM
REST APIs
DevOps
Databricks

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Bachelor’s or Master’s degree in Computer Science, Information Technology, Engineering, Information Systems, or a related discipline.
  • 9–13 years of overall experience in Quality Assurance, Software Testing, or Quality Engineering.
  • Significant experience leading Quality Assurance activities for large-scale enterprise applications and complex releases.
  • Strong experience in Salesforce functional and manual testing.
  • Hands-on experience with Copado Robotic Testing for Salesforce test automation.
  • Strong understanding of the Salesforce platform, preferably including Sales Cloud, Service Cloud, and/or Health Cloud.
  • Experience developing and maintaining automated regression test suites.
  • Experience testing Salesforce integrations, MuleSoft APIs, REST/SOAP services, and data interfaces.
  • Experience with end-to-end, integration, regression, API, and data validation testing.
  • Strong understanding of Agile/Scrum delivery methodologies and continuous integration/continuous delivery practices.
  • Familiarity with Copado, Jira, ServiceNow, or similar enterprise delivery and ticketing platforms.
  • Experience with test management and defect tracking tools.
  • Strong understanding of test automation strategy, quality gates, and release-readiness criteria.
  • Experience working in regulated environments.
  • Proven experience managing distributed onshore/offshore QA teams.
  • Ability to prioritize multiple testing activities and deliver under tight release timelines.
  • Ability to mentor QA engineers and promote testing and automation best practices.
Responsibilities
  • Lead end-to-end Quality Assurance activities for Salesforce applications and their integrated ecosystem.
  • Define and drive test strategy, test planning, execution, defect management, and reporting across releases.
  • Lead functional, integration, system, regression, end-to-end, and user acceptance testing.
  • Ensure test coverage reflects business requirements, user stories, acceptance criteria, technical designs, and integration specifications.
  • Serve as the primary Quality Assurance point of contact for product, business, engineering, and technology stakeholders.
  • Lead manual testing of Salesforce applications, including business processes, workflows, validations, security, profiles, permission sets, and user experience.
  • Design, review, and maintain test scenarios, test cases, test data, and expected results.
  • Validate complex Salesforce business processes across multiple objects, personas, applications, and integrations.
  • Drive exploratory and risk-based testing for business-critical capabilities.
  • Lead adoption and implementation of Copado Robotic Testing for Salesforce test automation.
  • Design and maintain reusable automated test suites using Copado Robotic Testing.
  • Identify manual regression scenarios for automation based on business criticality, repeatability, and return on investment.
  • Integrate automated testing into continuous integration/continuous delivery and release pipelines where applicable.
  • Monitor automation results, investigate failures, and maintain automated test scripts.
  • Define standards and best practices for Copado Robotic Testing development, execution, and maintenance.
  • Lead end-to-end testing across Salesforce and integrated enterprise platforms, including MuleSoft APIs, Databricks, and other upstream/downstream applications.
  • Validate API integrations, data transformations, interface processing, error handling, and data reconciliation.
  • Coordinate testing dependencies across application and technology teams.
  • Establish and enforce defect management, triage, prioritization, and closure processes.
  • Lead defect triage sessions and track defect trends, leakage, reopen rates, and recurring quality issues.
  • Drive root cause analysis for escaped production defects and implement preventive actions.
  • Establish quality gates and release-readiness criteria before production deployment.
  • Develop test plans and testing schedules aligned with sprint and release timelines.
  • Estimate Quality Assurance effort and determine testing capacity based on release scope and complexity.
  • Coordinate Quality Assurance activities across Agile sprints, major releases, hotfixes, patches, and production maintenance releases.
  • Assess testing risks and communicate potential impacts to release timelines.
  • Provide Quality Assurance sign-off and release-readiness recommendations.
  • Support post-production validation and hypercare testing following major releases.
  • Drive a quality engineering and automation-first approach.
  • Improve test efficiency through reusable test assets, automation, standardized processes, and optimized test data management.
  • Establish Quality Assurance standards, templates, metrics, and best practices across the delivery organization.
  • Promote shift-left testing during requirements, refinement, and solution-design activities.
  • Partner with Product Owners, Business Analysts, Architects, Developers, Scrum Masters, and Production Support teams.
  • Participate in requirements and user-story refinement to ensure requirements and acceptance criteria are clear, testable, and complete.
  • Act as the bridge between business and technology teams for quality-related discussions.
  • Communicate testing progress, risks, defects, dependencies, and release readiness to leadership and stakeholders.
  • Lead and mentor onshore/offshore QA and test automation teams.
  • Allocate QA resources based on release priorities and workload.
  • Provide technical and functional guidance to manual and automation testers.
  • Establish standards for test documentation, traceability, automation, and defect management.
  • Drive knowledge sharing, cross-skilling, and capability development within the QA team.
  • Mentor team members on Salesforce testing, Copado Robotic Testing, quality engineering, and testing best practices.
Desired Qualifications
  • Experience with enterprise data platforms such as Databricks.
  • Experience working in pharmaceutical, healthcare, or life sciences environments.
  • Understanding of GxP, compliance, data privacy, and validation requirements.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.